Innovative Approaches to Studying Cancer Communication in the New Media Environment (R21 - Clinical Trial Optional)
The summary for the Innovative Approaches to Studying Cancer Communication in the New Media Environment (R21 - Clinical Trial Optional) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Innovative Approaches to Studying Cancer Communication in the New Media Environment (R21 - Clinical Trial Optional): This Funding Opportunity Announcement (FOA) invites applications that seek to apply one or more innovative methodologies in communication research across the cancer control continuum, from prevention, early detection, diagnosis, treatment, and survivorship, to end of life. Applications to this FOA should utilize one or more of the following analytic approaches, methods, and data sources, including but not limited to social media data mining, Natural Language Processing (NLP) techniques, online social network analysis, crowdsourcing research tools (e.g., mTurk), online search data, Ecological Momentary Assessment, neuroscience and biobehavioral approaches to communication, and geographic information systems. Studies should assess outcomes related to cancer prevention and control (e.g., knowledge, attitudes, beliefs, perceived risk, decision making in screening and treatment, information inequalities, social support, shared decision making, persuasion, caregiving, behavioral intentions, preventive behaviors, and policy support, among others). This FOA utilizes the Exploratory/Developmental Grant (R21) mechanism, which supports investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. An R21 grant application need not have extensive background material or preliminary information.
Federal Grant Title: | Innovative Approaches to Studying Cancer Communication in the New Media Environment (R21 - Clinical Trial Optional) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Education Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PAR-18-639 |
Type of Funding: | Grant |
CFDA Numbers: | 93.395 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | June 13th, 2019 |
Original Application Deadline: | June 13th, 2019 |
Posted Date: | February 7th, 2018 |
Creation Date: | February 7th, 2018 |
Archive Date: | July 19th, 2019 |
Total Program Funding: | |
Maximum Federal Grant Award: | $200,000 |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | February 7th, 2018 |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/pa-files/PAR-18-639.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical...
- • Single Source: Pediatric Early Phase Clinical Trials Network (PEP-CTN; UM1 Clinical Trial ...
- • Assay development and screening for discovery of chemical probes, drugs or immunomodulator...
- • Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed)
- • The Blood and Marrow Transplant Clinical Trials Network - Core Clinical Centers (UG1 Clini...
- • Breast and Prostate Cancer Data Quality and Patterns of Care Study
- • Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults
- • National Cooperative Drug Discovery Groups for Cancer
- More Grants from the National Institutes of Health
- • Botanical Dietary Supplements Translational Research Teams (RM1 Clinical Trial Required)
- • Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)
- • Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clin...
- • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...
- • Limited Competition: Research Resource for Natural Product Nuclear Magnetic Resonance Data...